Compare SanDisk (SNDK) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

SNDK trades at $1,482.33, down 0.34% amid sector-wide pressure from Chinese competition concerns. The stock shows bearish technical signals with strong analyst support (87.5% buy rating) and a $2,160 consensus price target. Recent earnings beats contrast with current negative profitability, though 2026 projections show dramatic improvement to $11.4B net income. The company maintains strong balance sheet fundamentals with $1.48B cash and manageable debt levels.

SNDK presents a compelling risk-reward opportunity with significant upside potential to analyst targets, though near-term volatility from memory sector headwinds persists. The company's AI memory positioning and projected 2026 profitability growth support long-term bullish thesis, while current technical weakness may offer attractive entry points for patient investors.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.